Case reportGynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance
Section snippets
Case Reports
Patient A is a 54 year old transsexual male who began sex reassignment with androgen administration in 2000. Prior to this, he noted menarche at 12 years of age, and he had amenorrhea since 2000. He had not had prior intercourse with women since the age of 18 years. He denied any history of abnormal Papanicolaou smears or sexually transmitted diseases. His most recent normal Papanicolaou smear was in 2007. He denied any history of human immunodeficiency virus, intravenous drug use, or blood
Comment
Approximately 1 in 30,000 women per year undergo sex reassignment treatment. During the hormonal treatment process, therapy with androgens induces a hypoestrogenic state leading to amenorrhea. Such changes lead to atrophy of the endometrium. Long-term androgen therapy has also been found to be associated with cervical atrophy. Although to the best of our knowledge, there has not previously been reported a case of uterine or invasive cervical carcinoma in a cohort of patients treated with
References (8)
- et al.
Ovarian cancer in female-to male transsexuals: report of two cases
Gynecol Oncol
(2000) - et al.
Vaginal carcinoma in a female-to-male transsexual
J Sex Med
(2010) - et al.
Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient
Gynecol Obstet Invest
(2006) - et al.
Could a man be affected with carcinoma of cervix?The first case of cervical carcinoma in trans-sexual person (FtM)—case report
Acta Med (Hradec Kralove)
(2005)